You are here: Industry Insights > Pharmacovigilance

News List

What is MAH policy in China? ChatGPT/PharmaSources
November 09, 2023
In China, the Marketing Authorization Holder (MAH) system refers to a policy shift in the regulation of pharmaceutical products.
Suggesting on the best practice of becoming MAH of a drug in China ChatGTP/PharmaSources
November 09, 2023
Becoming a Marketing Authorization Holder (MAH) for a drug in China involves navigating a complex regulatory landscape.
Role of pharmacovigilance in innovating and revolutionising healthcare accessibility in India expresspharma
July 29, 2021
Dr Pramod Dhembare, Founder and Managing Partner, Fidelity Health Service, traces the role of pharmacovigilance in public healthcare.
Global pharmacovigilance market to value almost $15bn by 2028 europeanpharmaceuticalreview
April 29, 2021
Research suggests outsourcing and the increasing incidence of adverse drug reactions (ADR) will be primary drivers of growth in the global pharmacovigilance market.
Pharmacovigilance during a pandemic expresspharma
December 10, 2020
As coronavirus has become the new reality for every health worker and life science company to fight in the front, it is time to relook the approach being taken by the industry towards pharmacovigilance.
EMA releases findings from pharmacovigilance report europeanpharmaceuticalreview
December 19, 2019
A new pharmacovigilance document from the European Medicines Agency shows that the medicine safety system in the EU is effective.
Adjusted fees for EMA applicants from April 1st europeanpharmaceuticalreview
March 07, 2019
The EMA has announced that fees for new drug applications will be different from the beginning of April 2019, taking into account the rate of inflation…
Pharmacovigilance and drug safety outsourcing worth $207.7M by 2024 europeanpharmaceuticalreview
October 25, 2018
Outsourcing has become more popular with pharmaceutical companies, and has led to work being completed quicker, with less effort and cost involved…
EMA, MHRA and GlaxoSmithKline blast BMJ’s ‘flawed’ pandemic flu vaccine safety report fiercepharma
September 29, 2018
he EMA, MHRA and GSK criticized a BMJ report that suggests Pandemrix is less safe as scientifically “flawed and misleading.”
EMA, MHRA and GlaxoSmithKline blast BMJ’s ‘flawed’ pandemic flu vaccine safety report fiercepharma
September 29, 2018
The EMA, MHRA and GSK criticized a BMJ report that suggests Pandemrix is less safe as scientifically “flawed and misleading.”

Previous page 1 2 Next page